Vaccines in the era of genomics: The pneumococcal challenge

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 2963-2973

  Barocchi, Michèle Anne ^a   Censini, Stefano ^a   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Genomics; Global vaccine; Pangenome; Reverse vaccinology; Streptococcus pneumoniae

Indexed keywords

BACTERIAL ANTIGEN; BVH 11 ANTIGEN; MEMBRANE ANTIGEN; PIAA ANTIGEN; PILUS PROTEIN; PIUA ANTIGEN; PNEUMOCOCCUS SURFACE ADHESIN A; PNEUMOCOCCUS SURFACE PROTEIN A; PNEUMOCOCCUS SURFACE PROTEIN C; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE; POLYSACCHARIDE VACCINE; STREPTOCOCCUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; USP45 ANTIGEN;

BACTERIAL STRAIN; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; GENOME ANALYSIS; GENOMICS; HUMAN; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

EID: 33947638029     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.065     Document Type: Review

References (97)

1. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 3 5 (2000) 445-450
2. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
3. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 5731 (2005) 148-150
4. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
5. Klebs E. Beitrage zur Kentnis der pathogenen Schistomyceten. Die Monadinen Arch exp Pathol Pharmakol 4 (1875) 125-139
6. Sternberg G. A fatal form of septicemia in the rabbit, produced by the subcutaneous injection of human saliva. Natl Board Health Bull 2 781-783 (1881)
7. Pasteur L. Note sur la maladie nouvelle provoquee par la salive d'un enfant mort de la rage. Bull Acad Med 10 (1881) 94-103
8. Bergey D.B.R.G.N. Bergey's manual of determinative bacteriology (1974), Williams and Wilkins Co., Baltimore
9. Bridy-Pappas A.E., Margolis M.B., Center K.J., and Isaacman D.J. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 25 9 (2005) 1193-1212
10. Fedson D.S., and Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17 Suppl 1 (1999) S11-S18
11. Ostroff S. Global epidemiology of infectioius diseases. In: Mandell G.B., and Dolin J.E. (Eds). Mandell, Douglas, and Bennett's principles and practices of infectious diseases (2000), Churchill Livingstone, Philadelphia
12. Gray B.M., and Dillon Jr. H.C. Epidemiological studies of Streptococcus pneumoniae in infants: antibody to types 3, 6, 14, and 23 in the first 2 years of life. J Infect Dis 158 5 (1988) 948-955
13. Jacobs M.R. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 117 Suppl 3A (2004) 3S-15S
14. McCormick A.W., Whitney C.G., Farley M.M., Lynfield R., Harrison L.H., Bennett N.M., et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 9 4 (2003) 424-430
15. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33 10 (1995) 2759-2762
16. Bentley S.D., Aanensen D.M., Mavroidi A., Saunders D., Rabbinowitsch E., Collins M., et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2 3 (2006) e31
17. Sandgren A., Sjostrom K., Olsson-Liljequist B., Christensson B., Samuelsson A., Kronvall G., et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 189 5 (2004) 785-796
18. Bruckner R., Nuhn M., Reichmann P., Weber B., and Hakenbeck R. Mosaic genes and mosaic chromosomes-genomic variation in Streptococcus pneumoniae. Int J Med Microbiol 294 2-3 (2004) 157-168
19. Jefferies J.M., Smith A., Clarke S.C., Dowson C., and Mitchell T.J. Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. J Clin Microbiol 42 12 (2004) 5681-5688
20. Wizemann T.M., Heinrichs J.H., Adamou J.E., Erwin A.L., Kunsch C., Choi G.H., et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69 3 (2001) 1593-1598
21. Malley R., Lipsitch M., Stack A., Saladino R., Fleischer G., Pelton S., et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 69 8 (2001) 4870-4873
22. Wright A. Observations on prophylactic inoculation against pneumococus infections, and on the results which have been achieved by it. Lancet 1 (1914) 1-10 87-95
23. Group W.H.O.Y.I.S. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis 18 (1999) S17-S22
24. MacLeod C. Prevention of pneumococcal pneumoniae by immunization. J Exp Med 82 (1945) 445-465
25. Gay K., Baughman W., Miller Y., Jackson D., Whitney C.G., Schuchat A., et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 182 5 (2000) 1417-1424
26. Wuorimaa T., and Kayhty H. Current state of pneumococcal vaccines. Scand J Immunol 56 2 (2002) 111-129
27. Posfay-Barbe K.M., and Wald E.R. Pneumococcal vaccines: do they prevent infection and how?. Curr Opin Infect Dis 17 3 (2004) 177-184
28. Teele D.W., Klein J.O., Bratton L., Fisch G.R., Mathieu O.R., Porter P.J., et al. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev Infect Dis 3 Suppl (1981) S113-S118
29. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
30. Shinefield H., Black S., Ray P., Fireman B., Schwalbe J., and Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 21 3 (2002) 182-186
31. O'Brien K.L., Swift A.J., Winkelstein J.A., Santosham M., Stover B., Luddy R., et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 106 5 (2000) 965-972
32. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 14 (2003) 1341-1348
33. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 6 (2001) 403-409
34. Hausdorff W.P., Bryant J., Kloek C., Paradiso P.R., and Siber G.R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 30 1 (2000) 122-140
35. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 1 (2000) 100-121
36. WHO. Definition and evaluation of immune correlates of protection against children that can serve as the basis for licensure of future pneumococcal conjugate vaccines. Meeting minutes (2002), WHO, Anchorage, AK
37. Spratt B.G., and Greenwood B.M. Prevention of pneumococcal disease by vaccination: does serotype replacement matter?. Lancet 356 9237 (2000) 1210-1211
38. Huang S. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachussets communities, 2001 and 2004. Pediatrics 116 (2005) e408-e413
39. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 32 3 (2006) 139-153
40. Hammerschmidt S. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 9 1 (2006) 12-20
41. Mitchell T.J. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nat Rev Microbiol 1 3 (2003) 219-230
42. Talkington D.F., Brown B.G., Tharpe J.A., Koenig A., and Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 21 1 (1996) 17-22
43. Tart R.C., McDaniel L.S., Ralph B.A., and Briles D.E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 173 2 (1996) 380-386
44. Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62 12 (1994) 5683-5688
45. Roche H., Ren B., McDaniel L.S., Hakansson A., and Briles D.E. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun 71 8 (2003) 4498-4505
46. Gianfaldoni C., Censini S., Hilleringmann M., Moschioni M., Facciotti C., Pansegrau W., et al. Streptococcus penumoniae pilus subunits protect mice against lethal challenge. Infect Immunity 75 2 (2007) 1059-1062
47. McDaniel L.S., Sheffield J.S., Delucchi P., and Briles D.E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 59 1 (1991) 222-228
48. Rosenow C., Ryan P., Weiser J.N., Johnson S., Fontan P., Ortqvist A., et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25 5 (1997) 819-829
49. Paton J.C. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol 4 3 (1996) 103-106
50. Tilley S.J., Orlova E.V., Gilbert R.J., Andrew P.W., and Saibil H.R. Structural basis of pore formation by the bacterial toxin pneumolysin. Cell 121 2 (2005) 247-256
51. Briles D.E., Tart R.C., Swiatlo E., Dillard J.P., Smith P., Benton K.A., et al. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev 11 4 (1998) 645-657
52. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18 16 (2000) 1707-1711
53. Dintilhac A., Alloing G., Granadel C., and Claverys J.P. Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 25 4 (1997) 727-739
54. Romero-Steiner S., Pilishvili T., Sampson J.S., Johnson S.E., Stinson A., Carlone G.M., et al. Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies. Clin Diagn Lab Immunol 10 2 (2003) 246-251
55. Johnson S.E., Dykes J.K., Jue D.L., Sampson J.S., Carlone G.M., and Ades E.W. Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin a. J Infect Dis 185 4 (2002) 489-496
56. Seo J.Y., Seong S.Y., Ahn B.Y., Kwon I.C., Chung H., and Jeong S.Y. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 70 3 (2002) 1143-1149
57. Ogunniyi A.D., Folland R.L., Briles D.E., Hollingshead S.K., and Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68 5 (2000) 3028-3033
58. Iannelli F., Oggioni M.R., and Pozzi G. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 284 1/2 (2002) 63-71
59. Brooks-Walter A., Briles D.E., and Hollingshead S.K. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 67 12 (1999) 6533-6542
60. Cundell D.R., and Tuomanen E.I. Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro. Microb Pathog 17 6 (1994) 361-374
61. Ring A., Weiser J.N., and Tuomanen E.I. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. J Clin Invest 102 2 (1998) 347-360
62. Orihuela C.J., Gao G., Francis K.P., Yu J., and Tuomanen E.I. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 190 9 (2004) 1661-1669
63. Yother J., and White J.M. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol 176 10 (1994) 2976-2985
64. Jedrzejas M.J., Hollingshead S.K., Lebowitz J., Chantalat L., Briles D.E., and Lamani E. Production and characterization of the functional fragment of pneumococcal surface protein A. Arch Biochem Biophys 373 1 (2000) 116-125
65. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 69 2 (2001) 949-958
66. Hava D.L., and Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 45 5 (2002) 1389-1406
67. Hamel J., Charland N., Pineau I., Ouellet C., Rioux S., Martin D., et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72 5 (2004) 2659-2670
68. Barocchi M.A., Ries J., Zogaj X., Hemsley C., Albiger B., Kanth A., et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 103 8 (2006) 2857-2862
69. Lieu T.A., Finkelstein J.A., Adams M.M., Miroshnik I.L., Lett S.M., Palfrey S., et al. Pediatricians' views on financial barriers and values for pneumococcal vaccine for children. Ambul Pediatr 2 5 (2002) 358-366
70. Tettelin H., Nelson K.E., Paulsen I.T., Eisen J.A., Read T.D., Peterson S., et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293 5529 (2001) 498-506
71. Hoskins J., Alborn Jr. W.E., Arnold J., Blaszczak L.C., Burgett S., DeHoff B.S., et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 183 19 (2001) 5709-5717
72. Dopazo J., Mendoza A., Herrero J., Caldara F., Humbert Y., Friedli L., et al. Annotated draft genomic sequence from a Streptococcus pneumoniae type 19F clinical isolate. Microb Drug Resist 7 2 (2001) 99-125
73. Lanie JA, Ng WL, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ, et al. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol; 2006.
74. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 5459 (2000) 1809-1815
75. Field D., Wilson G., and van der Gast C. How do we compare hundreds of bacterial genomes?. Curr Opin Microbiol 9 5 (2006) 499-504
76. Medini D., Donati C., Tettelin H., Masignani V., and Rappuoli R. The microbial pan-genome. Curr Opin Genet Dev 15 6 (2005) 589-594
77. Tettelin H., Masignani V., Cieslewicz M.J., Donati C., Medini, Ward N.L., et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci USA 102 39 (2005) 13950-13955
78. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 21 (1991) 1453-1460
79. Levine O.S., O'Brien K.L., Knoll M., Adegbola R.A., Black S., Cherian T., et al. Pneumococcal vaccination in developing countries. Lancet 367 9526 (2006) 1880-1882
80. Sniadack D.H., Schwartz B., Lipman H., Bogaerts J., Butler J.C., Dagan R., et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr Infect Dis J 14 6 (1995) 503-510
81. Jebaraj R., Cherian T., Raghupathy P., Brahmadathan K.N., Lalitha M.K., Thomas K., et al. Nasopharyngeal colonization of infants in southern India with Streptococcus pneumoniae. Epidemiol Infect 123 3 (1999) 383-388
82. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., and Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 4 (1999) 1171-1176
83. Dagan R., Kayhty H., Wuorimaa T., Yaich M., Bailleux F., Zamir O., et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J 23 2 (2004) 91-98
84. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 9512 (2006) 740-748
85. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148 6 (1983) 1136-1159
86. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., and Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175 4 (1997) 839-846
87. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18 17 (2000) 1743-1754
88. Areas A.P., Oliveira M.L., Miyaji E.N., Leite L.C., and Ho P.L. Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae. Infect Immun 73 6 (2005) 3810-3813
89. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 2 (2000) 796-800
90. Balachandran P., Brooks-Walter A., Virolainen-Julkunen A., Hollingshead S.K., and Briles D.E. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70 5 (2002) 2526-2534
91. Brown J.S., Ogunniyi A.D., Woodrow M.C., Holden D.W., and Paton J.C. Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun 69 11 (2001) 6702-6706 Erratum in: Infect Immun 2004; 72(11):6755
92. Paton J.C., Lock R.A., and Hansman D.J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40 2 (1983) 548-552
93. Briles D.E., Hollingshead S.K., Paton J.C., Ades E.W., Novak L., van Ginkel F.W., et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188 3 (2003) 339-348
94. Garcia-Suarez Mdel M., Cima-Cabal M.D., Florez N., Garcia P., Cernuda-Cernuda R., Astudillo A., et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 72 8 (2004) 4534-4540
95. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., and Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75 1 (2007) 350-357
96. Zhang Y., Masi A.W., Barniak V., Mountzouros K., Hostetter M.K., and Green B.A. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 69 6 (2001) 3827-3836
97. Mattos-Graner R.O., Jin S., King W.F., Chen T., Smith D.J., and Duncan M.J. Cloning of the Streptococcus mutans gene encoding glucan binding protein B and analysis of genetic diversity and protein production in clinical isolates. Infect Immun 69 11 (2001) 6931-6941